
Sign up to save your podcasts
Or


The NRG Oncology Podcast Co-hosts sit with NRG-BR008 "HERO" Study Co-PIs Dr. Lior Braunstein and Dr. Melissa Mitchell to discuss this study for low-risk HER2+ breast cancer. This study will test if HER2-targeted therapy without radiation therapy is as good as the usual treatment of HER2-targeted therapy with radiation for patients with early-stage HER2+ breast cancer.
By NRG Oncology5
1010 ratings
The NRG Oncology Podcast Co-hosts sit with NRG-BR008 "HERO" Study Co-PIs Dr. Lior Braunstein and Dr. Melissa Mitchell to discuss this study for low-risk HER2+ breast cancer. This study will test if HER2-targeted therapy without radiation therapy is as good as the usual treatment of HER2-targeted therapy with radiation for patients with early-stage HER2+ breast cancer.

229,194 Listeners

6,785 Listeners

30,687 Listeners

8,766 Listeners

520 Listeners

29,785 Listeners

2,445 Listeners

112,946 Listeners

9,529 Listeners

61 Listeners

9,957 Listeners

16,095 Listeners

2,286 Listeners

37 Listeners

5 Listeners